Overview

Phase I Tolerability, Efficacy, and Safety Study of Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors

Status:
Recruiting

Trial end date:
2025-01-01

Target enrollment:

Participant gender:

Summary

This is a open-label non-randomized, dose escalation and expansion Phase Ia/Ib study to determine the safety, tolerability and maximum tolerated dose (MTD) of pazopanib in combination with PCI-24781 in patients with advanced solid tumors.

Phase:

Phase 1

Details

Lead Sponsor:

Pamela Munster
University of California, San Francisco

Collaborators:

GlaxoSmithKline
GlaxoSmithKline Research and Education Foundation for Cardiovascular Disease
Novartis
Pharmacyclics LLC.
Xynomic Pharmaceuticals, Inc.

Treatments:

Abexinostat